These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 24982227)
1. Comparative study of prescribing patterns of tigecycline for trial patients versus non-trial patients. Horscht JJ; Zimmermann JB; Weigand MA; Bruckner T; Martin EO; Hoppe-Tichy T; Swoboda S In Vivo; 2014; 28(4):589-94. PubMed ID: 24982227 [TBL] [Abstract][Full Text] [Related]
2. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409 [TBL] [Abstract][Full Text] [Related]
5. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy. Ramsamy Y; Muckart DJ; Han KS S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954 [TBL] [Abstract][Full Text] [Related]
6. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046 [TBL] [Abstract][Full Text] [Related]
7. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047 [TBL] [Abstract][Full Text] [Related]
8. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria. Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414 [TBL] [Abstract][Full Text] [Related]
9. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Dowzicky MJ; Park CH Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792 [TBL] [Abstract][Full Text] [Related]
18. Tigecycline: first of a new class of antimicrobial agents. Rose WE; Rybak MJ Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487 [TBL] [Abstract][Full Text] [Related]
19. Tigecycline: a new glycylcycline for treatment of serious infections. Noskin GA Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069 [TBL] [Abstract][Full Text] [Related]